OncoZenge AB (publ) (ONCOZ.ST)
SEK 3.97
(4.34%)
SEK 3.97
(4.34%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 20.34 Million SEK | -44.87% |
| 2022 | 36.89 Million SEK | -56.71% |
| 2021 | 85.22 Million SEK | 122.55% |
| 2020 | 38.29 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 17.23 Million SEK | -15.28% |
| 2024 Q2 | 14.93 Million SEK | -13.32% |
| 2023 Q1 | 31.6 Million SEK | -14.33% |
| 2023 Q4 | 20.34 Million SEK | -14.0% |
| 2023 Q2 | 27.82 Million SEK | -11.97% |
| 2023 FY | 20.34 Million SEK | -44.87% |
| 2023 Q3 | 23.65 Million SEK | -14.99% |
| 2022 FY | 36.89 Million SEK | -56.71% |
| 2022 Q2 | 43.24 Million SEK | -11.32% |
| 2022 Q4 | 36.89 Million SEK | -8.23% |
| 2022 Q1 | 48.76 Million SEK | -42.78% |
| 2022 Q3 | 40.2 Million SEK | -7.03% |
| 2021 Q2 | 83.58 Million SEK | -13.62% |
| 2021 FY | 85.22 Million SEK | 122.55% |
| 2021 Q4 | 85.22 Million SEK | 1.6% |
| 2021 Q3 | 83.88 Million SEK | 0.36% |
| 2021 Q1 | 96.76 Million SEK | 0.0% |
| 2020 FY | 38.29 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 82.828% |
| Ziccum AB (publ) | 14.97 Million SEK | -35.854% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -1.492% |
| BioArctic AB (publ) | 1.18 Billion SEK | 98.285% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 67.392% |
| Mendus AB (publ) | 755.95 Million SEK | 97.309% |
| Genovis AB (publ.) | 288.85 Million SEK | 92.958% |
| Intervacc AB (publ) | 259.61 Million SEK | 92.165% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 51.524% |
| Active Biotech AB (publ) | 44 Million SEK | 53.773% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 92.703% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 67.274% |
| Aptahem AB (publ) | 63.02 Million SEK | 67.727% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 95.901% |
| Kancera AB (publ) | 65.64 Million SEK | 69.014% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 94.211% |
| Fluicell AB (publ) | 9.34 Million SEK | -117.773% |
| Saniona AB (publ) | 64.14 Million SEK | 68.29% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 39.468% |
| Biovica International AB (publ) | 131.4 Million SEK | 84.521% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 61.612% |
| AcouSort AB (publ) | 34.51 Million SEK | 41.066% |
| Xintela AB (publ) | 18.39 Million SEK | -10.574% |
| Abliva AB (publ) | 87.49 Million SEK | 76.754% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 97.324% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 98.384% |
| Amniotics AB (publ) | 26.08 Million SEK | 22.027% |
| 2cureX AB (publ) | 16.62 Million SEK | -22.346% |
| CombiGene AB (publ) | 120.61 Million SEK | 83.136% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -234.705% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.93% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.934% |
| Corline Biomedical AB | 100.1 Million SEK | 79.681% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 88.516% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 85.533% |
| I-Tech AB | 152.44 Million SEK | 86.657% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 98.002% |
| Cyxone AB (publ) | 43.65 Million SEK | 53.407% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 74.152% |
| Biosergen AB | 7.2 Million SEK | -182.461% |
| Cantargia AB (publ) | 223.71 Million SEK | 90.908% |
| NextCell Pharma AB | 81.28 Million SEK | 74.978% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 97.342% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 32.589% |
| Nanologica AB (publ) | 77.42 Million SEK | 73.731% |
| SynAct Pharma AB | 228.01 Million SEK | 91.08% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 24.0% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 6.28% |
| LIDDS AB (publ) | 17.65 Million SEK | -15.208% |
| Lipum AB (publ) | 12.11 Million SEK | -67.96% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.547% |
| Alzinova AB (publ) | 123.18 Million SEK | 83.489% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 91.467% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -140.568% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 76.134% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -36.795% |
| Simris Alg AB (publ) | 174.55 Million SEK | 88.347% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 90.628% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 96.888% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 76.64% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 28.652% |